Prima BioMed Names Marc Voigt CEO, Replacing U.S.-based Matthew Lehman

(RTTNews) - Prima BioMed Ltd. (PBMD) Wednesday named Marc Voigt as its Chief Executive Officer, replacing Matthew Lehman. Lehman will however remain as an adviser to the company to facilitate an orderly transition. Following his appointment as CE0, Voigt will join the board as an Executive Director.

This appointment follows Prima's recent shift in its operational focus to Europe, where its clinical trials and manufacturing of CVac have been centralized to generate cost savings and enhance operational efficiencies. The company's European manufacturing facility is based in Leipzig, Germany where Prima benefits from a significant funding grant from the Saxony Development Bank to carry out its CVac development program in Europe.

Voigt, Prima's Chief Business Officer and Chief Financial Officer as well as General Manager of the company's European Operations, has over 16 years of experience in the financial and biotech industry. Prior to that, he had held different management roles with Revotar Biopharmaceuticals, Caprotec Bioanalytics and Medical Enzymes AG.